A systematic review of targeted agents for non-small cell lung cancer
HH Vestergaard, MR Christensen, UN Lassen - Acta oncologica, 2018 - Taylor & Francis
Background: advanced-stage non-small cell lung cancer (NSCLC) is characterized by
having limited treatment options and thus a poor prognosis. However, new treatment …
having limited treatment options and thus a poor prognosis. However, new treatment …
Protein tyrosine signaling and its potential therapeutic implications in carcinogenesis
M Kim, M Baek, DJ Kim - Current pharmaceutical design, 2017 - ingentaconnect.com
Protein tyrosine phosphorylation is a crucial signaling mechanism that plays a role in
epithelial carcinogenesis. Protein tyrosine kinases (PTKs) control various cellular processes …
epithelial carcinogenesis. Protein tyrosine kinases (PTKs) control various cellular processes …
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta …
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
[HTML][HTML] Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision
AC Sousa, C Silveira, A Janeiro, S Malveiro… - Lung Cancer, 2020 - Elsevier
Objectives Mutations in the gene that encodes epidermal growth factor receptor (EGFR) are
biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR …
biomarkers that predict how non-small cell lung cancer (NSCLC) patients respond to EGFR …
[HTML][HTML] Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
S Lu, M Ye, L Ding, F Tan, J Fu, B Wu - Oncotarget, 2017 - ncbi.nlm.nih.gov
Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) are becoming the
standard treatment option for patients with advanced non-small cell lung cancer (NSCLC) …
standard treatment option for patients with advanced non-small cell lung cancer (NSCLC) …
[HTML][HTML] Epidermal growth factor receptor mutation frequency in squamous cell carcinoma and its diagnostic performance in cytological samples: a molecular and …
Background Epidermal growth factor receptor (EGFR) mutation is the most frequent mutation
tested in lung cancer for targeted therapy in the era of personalized medicine. Knowledge …
tested in lung cancer for targeted therapy in the era of personalized medicine. Knowledge …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - PloS one, 2020 - journals.plos.org
Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
Efficacy of afatinib in the treatment of patients with non-small cell lung cancer and head and neck squamous cell carcinoma: a systematic review and meta-analysis
NNN Maarof, A Alsalahi, E Abdulmalek, S Fakurazi… - Cancers, 2021 - mdpi.com
Simple Summary Evidence from randomized controlled trials about the efficacy of
monotherapy of afatinib on survival of patients with advanced non-small cell lung cancer …
monotherapy of afatinib on survival of patients with advanced non-small cell lung cancer …
Testin is a tumor suppressor in non-small cell lung cancer
M Wang, Q Wang, WJ Peng, JF Hu… - Oncology …, 2017 - spandidos-publications.com
The Testin gene was previously identified in the fragile chromosomal region FRA7G at 7q31.
2. It has been implicated in several types of cancers including prostate, ovarian, breast and …
2. It has been implicated in several types of cancers including prostate, ovarian, breast and …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
CTT Nguyen, F Petrelli, S Scuri, BT Nguyen… - The European Journal of …, 2019 - Springer
Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …